Taffic

Bictegravir/Emtricitabine/Tenofovir Alafenamide

Price range: $90.00 through $230.00

Tablets
Choose an option
Taffic
Add to cart
Buy Now
SKU: N/A Category:
๐Ÿท๏ธย Parameter ๐Ÿ”ย Details
๐Ÿงฌ Active Ingredients Bictegravir 50mg + Emtricitabine 200mg + Tenofovir Alafenamide 25mg
๐Ÿ’Š Indication HIV-1 Infection (First-line ART for adults/adolescents โ‰ฅ25kg)
๐Ÿ‡บ๐Ÿ‡ธ US Brand Biktarvyยฎ
๐Ÿญ Manufacturer Hetero Drugs Ltd.
๐Ÿ“ฆ Packaging 30 tablets in 1 HDPE bottle
๐Ÿ’ช Strength 50mg/200mg/25mg per tablet
๐Ÿšš Delivery Time 7โ€“14 days (Worldwide)

๐Ÿงฌ Introduction to Taffic

Taffic by Hetero Drugs is aย cutting-edge HIV regimenย combining:

  • ๐Ÿงฉย Bictegravir 50mgย (INSTI: integrase strand transfer inhibitor)

  • ๐Ÿงฌย Emtricitabine 200mgย (NRTI: cytidine analog with dual HIV/HBV activity)

  • ๐Ÿ›ก๏ธย Tenofovir Alafenamide 25mgย (TAF: nephro-safe prodrug of tenofovir)

Approved forย HIV-1 treatment in patients โ‰ฅ25kg, this 30-tablet bottle offers:

  • โœ… Once-daily dosing (any food/timing)

  • โœ… Superior renal/bone safety vs. TDF-based regimens

  • โœ… High genetic barrier to resistance

  • โœ… First-line WHO-recommended regimen

  • โ— Caution with concomitant rifampicin

Hetero’s generic version provides affordable access to this gold-standard therapy.


๐Ÿ’Š Dosage & Indications

๐Ÿ’‰ย Indication ๐Ÿงชย Dosage โฑ๏ธย Frequency ๐Ÿ’กย Notes
Adults โ‰ฅ25kg 1 tablet Once daily With or without food
Adolescents (25-35kg) Not recommended โ€“ Use pediatric formulations
Renal Impairment Avoid if eGFR <30 mL/min Contraindicated TAF accumulation risk
HBV Co-infection Never discontinue abruptly โ€“ Monitor for HBV flare

โš ๏ธ Side Effects, Storage & Warnings

  • โ— Common Side Effects:

    • Headache (10%)

    • Diarrhea (7%)

    • Nausea (6%)

  • ๐Ÿšซ Rare Serious Effects:

    • Immune reconstitution syndrome

    • Lactic acidosis (0.1%)

    • Hepatomegaly with steatosis

  • โ„๏ธ Storage: 15โ€“30ยฐC; keep bottle tightly closed (desiccant included).

  • โš ๏ธ Critical Warnings:

    • Contraindicatedย with rifampicin or carbamazepine

    • Test for HBV before initiation

    • Monitor eGFR/urine protein annually


๐ŸŒ Global Availability & Shipping

๐ŸŒŽย Region ๐Ÿ“ฆย Shipping ๐Ÿ’ตย Price (30-tablet bottle) ๐Ÿ“œย Prescription
๐Ÿ‡บ๐Ÿ‡ธ USA โœ… Yes $90โ€“$150 Required
๐Ÿ‡ฌ๐Ÿ‡ง UK โœ… Yes ยฃ70โ€“ยฃ120 Required
๐Ÿ‡ฆ๐Ÿ‡บ Australia โœ… Yes AUD 130โ€“190 Required

๐Ÿ”— Related Indian Alternatives (Different in Same Category)

๐Ÿ’Š Product Name ๐Ÿญ Manufacturer ๐Ÿ”— Internal Link
Dolutranz (Dolutegravir/Tenofovir) Mylan dolutranz
Tenof-EM (Tenofovir/Emtricitabine) Hetero tenof-em
Viraday (Efavirenz/FTC/TDF) Cipla viraday
Tavin-EM (TAF/FTC) Cipla tavin-em
DoloVir (Dolutegravir/TAF/FTC) Hetero dolovir
Covihope-D (Dolutegravir/Ritonavir) Hetero covihope-d

๐Ÿ“š External Medical References

  1. WHO: Updated HIV Treatment Guidelines 2023

  2. FDA: Biktarvy Prescribing Information

  3. IAS-USA: Antiretroviral Drug Interactions


๐Ÿฉบ Expert Commentary

Dr. Meena Krishnan, HIV Researcher:
“Taffic’s Bictegravir has negligible neuropsychiatric effects compared to Efavirenz-based regimens. For patients on rifampicin TB therapy, switch to [dolovir] (Dolutegravir-based). Hetero’s bottle includes oxygen absorber to maintain TAF stability in humid climates.”


๐Ÿ“Œ Disclaimer

This information is not medical advice. Use under physician supervision. Heteroโ€™s Taffic must not be used for HBV monotherapy.


๐Ÿ’ก Clinical Protocol:

  • HBV Co-infection Protocol:

    • Test HBV surface antigen before starting

    • If positive: Monitor LFTs monthly ร—3, then quarterly

    • Never interrupt therapy (risk of fatal hepatitis flare)

  • Bottle Specifications:

    • White HDPE bottle with induction seal

    • Tablet ID: “H” logo + “TFC” engraving

    • Oxygen scavenger sachet (do not remove)

  • Drug Interactions:

    Concomitant Drug Risk Action
    Rifampicin โ†“ Bictegravir levels 75% Contraindicated
    Antacids โ†“ Bictegravir absorption Separate by 2 hours
    Dabigatran โ†‘ Bleeding risk Monitor aPTT
  • Renal Monitoring Schedule:

    Parameter Frequency Action Threshold
    eGFR Baseline, Annual Decline >25%
    Urine Protein/Creatinine Annual Ratio >200 mg/g
    Serum Phosphate If symptoms <2.0 mg/dL

Additional Information

active

Tablets

30, 60, 90

Reviews

There are no reviews yet.

Be the first to review “Taffic”
Top